These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30954469)

  • 41. Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.
    Nghiem-Buffet S; Baillif S; Regnier S; Skelly A; Yu N; Sodi A
    Eye (Lond); 2017 Apr; 31(4):551-559. PubMed ID: 27911446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Collateral Vessel Development in Central and Branch Retinal Vein Occlusions Are Associated With Worse Visual and Anatomic Outcomes.
    Arrigo A; Aragona E; Lattanzio R; Scalia G; Bandello F; Parodi MB
    Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):1. PubMed ID: 34724540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.
    Blanc J; Deschasse C; Kodjikian L; Dot C; Bron AM; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1441-1448. PubMed ID: 29855706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Chen AX; Greenlee TE; Conti TF; Briskin IN; Singh RP
    Ophthalmol Retina; 2020 Dec; 4(12):1158-1169. PubMed ID: 32480014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes in Retinal Vein Occlusions Presenting with Poor Visual Acuity Treated with Anti-Vascular Endothelial Growth Factor Therapy: Prognosis and Predictive Factors.
    Light JG; Tian J; Wenick AS
    Ophthalmol Retina; 2021 Sep; 5(9):888-900. PubMed ID: 33227561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.
    Sophie R; Hafiz G; Scott AW; Zimmer-Galler I; Nguyen QD; Ying H; Do DV; Solomon S; Sodhi A; Gehlbach P; Duh E; Baranano D; Campochiaro PA
    Am J Ophthalmol; 2013 Oct; 156(4):693-705. PubMed ID: 24053892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Short term results of intra-vitreal bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Thapa R; Poudyal G
    Nepal J Ophthalmol; 2013; 5(1):63-8. PubMed ID: 23584649
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
    Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
    Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: A meta-analysis.
    Qian T; Zhao M; Xu X
    J Clin Pharm Ther; 2017 Oct; 42(5):519-529. PubMed ID: 28639290
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
    Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
    Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal Injection of Anti-Vascular Endothelial Growth Factors Combined with Corticosteroids for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review and Meta-Analysis.
    Namvar E; Yasemi M; Nowroozzadeh MH; Ahmadieh H
    Semin Ophthalmol; 2024 Jan; 39(1):109-119. PubMed ID: 37621098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; de Jong-Hesse Y; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Jun; 4(6):576-587. PubMed ID: 32107188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
    Haller JA; Bandello F; Belfort R; Blumenkranz MS; Gillies M; Heier J; Loewenstein A; Yoon YH; Jacques ML; Jiao J; Li XY; Whitcup SM;
    Ophthalmology; 2010 Jun; 117(6):1134-1146.e3. PubMed ID: 20417567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
    Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
    Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ranibizumab for serous macular detachment in branch retinal vein occlusions.
    Gallego-Pinazo R; Dolz-Marco R; Pardo-López D; Martínez-Castillo S; Lleó-Pérez A; Arévalo JF; Díaz-Llopis M
    Graefes Arch Clin Exp Ophthalmol; 2013 Jan; 251(1):9-14. PubMed ID: 22527327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy.
    Suzuki M; Nagai N; Minami S; Kurihara T; Kamoshita M; Sonobe H; Watanabe K; Shinoda H; Tsubota K; Ozawa Y
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):49-56. PubMed ID: 31732812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
    Kim M; Jeong S; Sagong M
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.
    Sangroongruangsri S; Ratanapakorn T; Wu O; Anothaisintawee T; Chaikledkaew U
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):903-916. PubMed ID: 30071180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Li F; Sun M; Guo J; Ma A; Zhao B
    Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
    Ozkaya A; Tarakcioglu HN; Tanir I
    Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.